Table 1. Clinical data and tumour characteristics at the time of initial diagnosis and imatinib induction, and response to imatinib in 17 patients with malignant GIST.

	Status at initial diagnosis					Status at imatinib induction			Imatinib treatment
Case	Age/sex	1° tumour site and size (cm)	Ki67%/MR	Exon 11 KIT mutation	Mets at initial diag.	Number previous surgeries	Interval: 1° tumour diag to imatinib (months)	Disease status	Clinical setting	FU (months)	Response CT eval.	Response PET eval.	Side effects
1	56/M	SB/20	10%/2–5	W557R	L	None	3	PT, P, L	Neoadjuvant	10	PR	No residual uptake	None
2	48/M	R/9	10%/2–5	K558_V560del	None	1	1.5	NEDa	Adjuvant	13	NED	No uptake	None
3	55/M	R/4.5	5%/<2	W557M	None	2	180	NEDb	Adjuvant	12	NED	Not done	None
4	10/F	S/3.5	5%c/2–5	None	None	5	144	NEDd	Adjuvant	9.5	NED	No uptake	Oedema grade 2
5	74/M	D/11	15%/6–10	None	None	2	22	P, L	Palliative	13	PD	Additional uptake	Oedema grade 1
6	70/M	D/25	25%/6–10	None	L	1	1	PT, L	Palliative	9	PD	Not done	None
7	47/M	SB/29	30%/>10	W557_E561del	P	1	7	PT, P, L	Palliative	14.5	PR	No residual uptake	None
8	63/M	SB/15	50%/2–5	None	P, L	2	3	P, L	Palliative	9	PR	Decreased uptake	None
9	70/M	SB/16	20%/>10	V559_E561del	P, L	3	14	P, L	Palliative	18	PR	Not done	None
10	72/M	SB/12	10%/>10	N564_L576del	P, L	1	3	P, L	Palliative	9.5	PR	Not done	None
11	53/M	SB/6	10%/>10	P551del,M552L	L	1	4	L	Palliative	14.5	PR	Not done	Oedema grade 2
12	62/M	SB/5	10%/>10	None	None	1	16	Pu	Palliative	9	SD	Not done	None
13	56/M	D/6	5%/6–10	K558_V559del, V560I	None	5	84	P, L	Palliative	12.5	PR	Not done	Oedema grade 1
14	68/F	SB/10	10%/6–10	V559del	None	2	12	L	Palliative	6	PR	No residual uptake	None
15	36/M	SB/10	5%/2–5	W557_K558del	P	1	4	NED	Adjuvant	7	NED	No uptake	None
16	62/M	R/15	15%/6–10	P551_E554del	None	1	2	NEDa	Adjuvant	7	NED	No uptake	None
17	74/M	R/30	25%/>10	K558S,V559del	P	1	9	P	Palliative	8	PR	No residual uptake	None

D=duodenum; del=deletion; diag.=diagnosis; eval.=evaluation; F=female; FU=follow-up; L=liver mets; M=male; mets=metastases; MR=mitotic rate (mitoses/50 h.p.f.); NED=no evidence of disease; P=peritoneal mets; PD=progressive disease (>20% increase in the greatest diameter of the target lesion or appearance of one or more new lesions); PR=partial response (>30% decrease in the greatest diameter of target lesion); PT=primary tumour; Pu=pulmonary mets; R=rectum; S=stomach; SB=small bowel; SD=stable disease; 1°=primary;

^aResection of primary rectal GIST with intralesional margins.

^bResection of local recurrence with intralesional margins.

^cFocally 25% of cells positive for Ki67.

^dAfter five surgical procedures for peritoneal mets and liver mets.